MicroRNA‑125b inhibits the proliferation of vascular smooth muscle cells induced by platelet‑derived growth factor BB

Introduction

Lower extremity arteriosclerosis obliterans (ASO) refers to the deposition of lipids on the blood vessel walls of lower limbs, which is rapidly relieved by interventional therapy (1). However, the 1-year recurrence rate of stenosis is 30-50% (2). Therefore, it is crucial to identify the molecular mechanisms underlying the ASO process to provide novel strategies for clinical treatments. Excessive proliferation and migration of vascular smooth muscle cells (VSMCs), mainly caused by the monocyte/macrophage-induced inflammatory response, serve pivotal roles in ASO progression and restenosis following treatment (3). Therefore, the prevention and relief of dysfunction of VSMCs are important for ASO treatment.

MicroRNAs (miRNAs/miRs) are involved in the occurrence and progression of ASO. For example, miR-30b-5p is involved in the differentiation of VSMCs through interaction with muscleblind like splicing regulator 1(4). In addition, miR-143/145 inhibits the proliferation of VSMCs by regulating the expression of mammalian transcription factors and myocardin (5,6). These findings confirm the importance of miRNAs in regulating the dysfunction of VSMCs. The expression of miR-125b is notably altered in ASO (7). For example, a previous study demonstrated that miR-125b expression decreases in VSMCs and miR-125b inhibits the proliferation and migration of VSMCs (7). However, the underlying molecular mechanism of miR-125b in ASO remains unclear. Therefore, it is critical to investigate the potential promoting effects of miR-125b on ASO progression to identify novel treatment strategies for ASO.

The present study aimed to investigate the role of miR-125b in ASO by simulating ASO with platelet-derived growth factor-BB (PDGF-BB). The effect of PDGF-BB on miR-125b expression was investigated. Subsequently, A10 cells were treated with PDGF-BB to compare the effects of upregulated miR-125b expression on the proliferative and migratory abilities of VSMCs. The potential targets of miR-125b in VSMCs were also investigated.

Materials and methods

Cell culture

A10 cells from rat VSMCs were used in the present study. The A10 cell line was purchased from The Cell Bank of Type Culture Collection of The Chinese Academy of Sciences. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 U/ml streptomycin (Thermo Fisher Scientific, Inc.) at 37˚C with 5% CO2. PDGF-BB (20 ng/ml; PeproTech, Inc.), was used to investigate the effect of PDGF-BB on miR-125b expression.

miR-125b mimic and inhibitor transfection

A10 cells were seeded into 6-well plates (3x105 cells per well) for 24 h and subsequently transfected with miR-125b mimic or miR-125b inhibitor in parallel with their respective control oligos (60 nmol/l; Shanghai GenePharma Co., Ltd.) for 24 h at 37˚C using Lipofectamine® 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and Opti-MEM (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. The sequences of miR-125b mimic and inhibitor were as follows: miR-125b mimic forward, 5'-UCCCUGAGACCCUAACUUGUGA-3' and reverse, 5'-UCACAAGUUAGGGUCUCAGGGA-3'; NC mimic forward, 5'-UUUGUACUACACAAAAGUACUG-3' and reverse, 5'-CAGUACUUUUGUGUAGUACAAA-3'; miR-125b inhibitor, 5'-UCACAAGUUAGGGUCUCAGGGA-3' and NC inhibitor, 5'-CAGUACUUUUGUGUAGUACAAA-3'. After RNA interference was performed, the cells were cultured for an additional 48 h. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to assess the efficiency of miR-125b transfection.

RT-qPCR

Cells with different treatments were collected and total RNA was extracted using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed into cDNA according to the manufacturer's instructions of the PrimeScript RT Reagent kit (cat. no. RR047A; Takara Biotechnology Co., Ltd.). mRNA expression was analyzed using a 7500 Fast™ system (Applied Biosystems; Thermo Fisher Scientific, Inc.) and a Sensi Mix SYBR kit (QP10005; OriGene Technologies, Inc.). The PCR conditions were as follows: 95˚C for 10 sec, 95˚C for 5 sec and 60˚C for 20 sec (35 cycles), followed by 95˚C for 15 sec, and 65˚C for 10 sec. The following primer sequences were used for the qPCR: miR-125b forward, 5'-GCGCTCCCTGAGACCCTAAC-3' and reverse, 5'-TGCAGGGTCCGAGGTAT-3'; and U6 forward, 5'-CTCGCTTCGGCAGCACA-3' and reverse, 5'-AACGCTTCACGAATTTGCGT-3'. Relative expression levels were calculated using the 2-∆∆Ct method (8) and normalized to the internal reference gene U6.

Cell proliferation assay

Cell proliferation was assessed via Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology) and BrdU assays. For the CCK-8 assay, In brief, 2x103 cells were seeded into 96-well plates with 200 µl culture medium. Subsequently, 20 µl CCK-8 regent was added into each well after 24 h incubation at 37˚C, and then were incubated at 37˚C in dark for another 4 h. The optical density (OD) values were detected at 450 nm using a microplate reader (Tecan Group, Ltd.). Cell proliferation was quantified by standard curves, and a linear standard curve was fitted for log [cell quantity] and OD. For the BrdU assay, cells were seeded into 24-well plates for 24 h at 37˚C, followed by different treatments. Cell proliferation was assessed using the BeyoClick™ EDU-647 system (Beyotime Institute of Biotechnology) at a wavelength of 450 nm.

Transwell assay

For the Transwell assay, 5x104 cells with different treatments were plated into the upper chambers (24-well, 8.0 µm, Corning, Inc.) with serum free medium, and medium supplemented with 10% FBS was plated into the lower chambers. After 48 h incubation at 37˚C with 5% CO2, the migratory cells were stained with 0.5% crystal violet for 15 min at room temperature and observed under a light microscope (magnification, x100; Olympus Corporation).

Wound healing assay

For the wound healing assay, cells were seeded into 6-well plates until they reached 80% confluence. The cell monolayers were scratched using 200 µl pipette tips, washed with PBS to remove the detached cells and cultured in DMEM with 0.5% FBS for 48 h. The wound distance was observed under a light microscope (magnification, x200; Olympus Corporation).

Western blotting

Cells with different treatments were harvested with a cytology brush, washed with ice-cold PBS and lysed using RIPA lysis buffer (Sigma-Aldrich; Merck KGaA), containing a phosphorylase and protease inhibitor mixture (Thermo Fisher Scientific, Inc.). Total protein was quantified via the BCA assay. Proteins (40 µg per lane) were separated by 10% SDS-PAGE, separated proteins were transferred to PVDF membranes, which were subsequently blocked with Tris-buffered saline with Tween solution (0.1% Tween-20) and 5% skimmed milk at 4˚C overnight. The membranes were incubated with primary antibodies against SRF (dilution, 1:1,000; cat. no. 16821-1-AP; ProteinTech Group, Inc.), AAMP (dilution, 1:1,000; cat. no. 21220-1-AP; ProteinTech Group, Inc.) and GAPDH (dilution, 1:10,000; cat. no. ab9385; Abcam) at 4˚C overnight. Following incubating with the primary antibody, membranes were incubated with secondary antibodies [horseradish peroxidase-conjugated goat anti rabbit IgG (1:5,000; cat. no. ab6721) or goat anti mouse IgG (1:2,000; cat. no. ab6789; Abcam)] for 1.5 h at room temperature, which was performed in TBS-Tween solution containing 5% skimmed milk. ECL chemiluminescence (Thermo Fisher Scientific, Inc.) was followed by exposure and development. ImageJ software (version 1.46; National Institutes of Health) was used for analysis.

Immunofluorescence

In brief, A10 cells were seeded into 24-well plates for 24 h and fixed with 4% paraformaldehyde at 4˚C for 30 min, followed by permeabilization with 0.5% Triton X-100 and blocking with 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA) at room temperature for 30 min. Samples were incubated with primary antibodies against SRF (dilution, 1:200; cat. no. 16821-1-AP; ProteinTech Group, Inc.) and AAMP (dilution, 1:200; cat. no. 21220-1-AP; ProteinTech Group, Inc.) overnight at 4˚C. Samples were subsequently washed with PBS and incubated with secondary antibodies for 1 h at room temperature, prior to re-washing. Nuclei were stained with 15 µl DAPI (Sigma-Aldrich; Merck KGaA) for 2 min at room temperature, prior to being observed under a fluorescence microscope (magnification, x200; Carl Zeiss AG).

Statistical analysis

Statistical analysis was performed using SPSS 20.0 software (IBM Corp.). All experiments were performed for three repeats excluding for Western blotting, which was only conducted once. Data are presented as the mean ± standard deviation. Paired Student's t-test was used to compare differences between two groups, while one-way analysis of variance and the Tukey's post hoc test were used to compare differences among multiple groups. P<0.05 was considered to indicate a statistically significant difference.

Results

PDGF-BB negatively regulates miR-125b expression in VSMCs

To determine the effect of PDGF-BB on miR-125b expression, miR-125b expression levels in VSMCs with or without PDGF-BB treatment were compared. As presented in Fig. 1, treatment with PDGF-BB significantly decreased miR-125b expression in VSMCs (~80%; P=0.0004). Notably, overexpression of miR-125b significantly rescued miR-125b expression following treatment with PDGF-BB (~40% upregulation; P=0.03).

Figure 1 PDGF-BB inhibits miR-125b expression in VSMCs. (A) Treatment with PDGF-BB decreases miR-125b expression, the effects of which are reversed following transfection of A10 cells with miR-125b mimic. (B) Treatment with PDGF-BB decreases miR-125b expression, the effects of which are reversed following transfection of A10 cells with miR-125b inhibitor. Data are presented as the mean ± standard deviation. One-way analysis of variance and the Tukey's post hoc test were used. *P<0.05, ***P<0.001. PDGF-BB, platelet-derived growth factor-BB; miR, microRNA; VSMCs, vascular smooth muscle cells; NC, negative control.

miR-125b inhibits the proliferation of VSMCs

To investigate the role of miR-125b on the proliferation of VSMCs, the CCK-8 and BrdU assays were performed. The results of the CCK-8 assay indicated that the OD value was decreased in the miR-125b mimic group compared with the NC group (P<0.001; Fig. 2A); therefore, the overexpression of miR-125b inhibited the proliferation of VSMCs. Furthermore, the results of the BrdU assay demonstrated that transfection with miR-125b mimic significantly decreased the OD value at day 4 (~40%), compared with the NC group (P<0.001; Fig. 2B). Taken together, these results suggested that miR-125b inhibits cell proliferation.

Figure 2 miR-125b inhibits the proliferation of VSMCs. (A) Cell Counting Kit-8 assay indicated that transfection with miR-125b mimic decreased the OD value at a wavelength of 450 nm, which is approximately half of the NC group. (B) The BrdU assay demonstrated that transfection with miR-125b mimic significantly inhibited the OD value at day 4. Data are presented as the mean ± standard deviation. Paired Students' t-test was used. ***P<0.001. miR, microRNA; VSMCs, vascular smooth muscle cells; OD, optical density; NC, negative control; OD, optical density; NC, negative control.

miR-125b inhibits the migration of VSMCs

To investigate the role of miR-125b on the migration of VSMCs, Transwell migration and wound healing assays were performed. The results of the Transwell assay demonstrated that the number of migratory cells significantly decreased in the miR-125b mimic group compared with the NC group (P<0.05; Fig. 3A). As presented in Fig. 3B, there were few differences between the NC and miR-125b mimic groups after 24 h. However, following 48 h of incubation, the cells had almost completely migrated into the wound in the NC group, while the gaps remained visible in the miR-125b mimic group. Following normalization, the migratory ability in the miR-125b mimic group was ~88% of that in the NC group (P<0.05).

Figure 3 miR-125b inhibits the migratory ability of VSMCs. (A) Transwell migration assay demonstrated that cells migrated in the miR-125b mimic group and NC group. Images presented from three different fields. (B) Wound healing assay was performed to assess the migratory ability of VSMCs in the miR-125b mimic group and NC group at 24 and 48 h. Data are presented as the mean ± standard deviation. Paired Student's t-test was used. *P<0.05. miR, microRNA; VSMCs, vascular smooth muscle cells; NC, negative control.

AAMP and SRF are targets of miR-125b in VSMCs

The present study investigated the association between miR-125b expression and AAMP and SRF expression. The results demonstrated that the protein expression levels of AAMP and SRF were significantly downregulated following transfection with miR-125b mimic, the effects of which were reversed following transfection with miR-125b inhibitor (P<0.05; Fig. 4A and B). Immunofluorescence analysis demonstrated that the miR-125b mimic-induced downregulation of AAMP and SRF was very slight, while miR-125b inhibitor-induced upregulation of AAMP and SRF expression levels was significant (Fig. 4C and D).

Figure 4 miR-125b negatively regulates AAMP and SRF. (A) Western blot analysis was performed to detect the protein expression levels of AAMP and SRF. (B) Semi-quantification of AAMP and SRF protein expression levels. Immunofluorescence assay was performed to detect (C) AAMP and (D) SRF expression. Data are presented as the mean ± standard deviation. One-way analysis of variance and the Tukey's post hoc test were used. *P<0.05, ***P<0.001. miR, microRNA; AAMP, angio-associated migratory cell protein; SRF, serum response factor; NC, negative control.

Discussion

Lower extremity ASO is induced by atherosclerotic thrombosis, which causes narrowing or occlusion of the lower extremity arteries, and the persistent ischemia eventually leads to tissue necrosis (9). The prevalence of ASO increases with age, which affects ~8-10% of people >65 years and ~20% of people >80 years (9). ASO is initiated following the accumulation of lipoproteins in the endothelium due to the abnormal metabolism of glucose and lipid (1,10). This in turn results in a series of intracellular reactions, which eventually induces vascular endothelial damage and the monocyte/macrophage-induced inflammatory response (11). Inflammatory cells and factors regulate the function of VSMCs, including cell proliferation, migration, differentiation and matrix secretion (11). VSMCs are the major cellular components that make up the middle layer of the arteries and are involved in the process of vascular diseases. At present, it is believed that the excessive proliferation and migration of VSMCs is one of the main causes of ASO, and it is also the main cause of restenosis following interventional treatment (10). Therefore, the prevention and relief of dysfunction of VSMCs are important for ASO treatment.

PDGF-BB derived from platelets is considered as a mediator of VSMC dysfunction and restenosis (12). PDGF-BB is a well-known atherosclerosis promotional factor (13). In the present study, PDGF-BB was used to imitate ASO. The effect of PDGF-BB treatment on miR-125b expression in VSMCs was investigated. The results demonstrated that miR-125b expression was significantly decreased following treatment with PDGF-BB, the effects of which were reversed following transfection with the miR-125b mimic. The present study used PDGF-BB to treat cells to determine the effect of the miR-125b mimic on the migratory and proliferative abilities of VSMCs. The CCK-8 and BrdU assays were performed to assess cell proliferation following treatment with PDGF-BB and transfection with miR-125b mimic. The results demonstrated that miR-125b mimic significantly inhibited cell proliferation. Furthermore, the results of the Transwell and wound healing assays demonstrated that miR-125b mimic decreased cell migration. Taken together, these results suggested that miR-125b serves an important role in ASO, which is consistent with previous findings (8).

Previous studies have demonstrated that miR-125b expression is downregulated in a variety of tumor cells, including hepatocellular carcinoma, breast cancer, ovarian tumors, bladder cancer and leukemia (14-18). Downregulation of miR-125b enhances the cell proliferative and invasive abilities. In ASO, miR-125b is one of the miRNAs that is significantly downregulated (7). It has been suggested that miR-125b can inhibit the proliferation and migration of VSMCs, and the molecular mechanisms are associated with the regulation of SRF or myosin 1E, respectively (7,19). However, miRNAs and their targets are complex and diverse (20). There is no clear evidence that miR-125b affects AAMP. AAMP is highly expressed in cancer cells, and its high expression is associated with the poor prognosis of patients with cancer (21). In the present study, miR-125b mimic and inhibitor were used to assess the effect of miR-125b expression levels on AAMP and SRF expression. Western blot analysis demonstrated that the protein expression levels of AAMP and SRF were significantly decreased following transfection with miR-125b mimic, the effects of which were reversed following transfection with the miR-125b inhibitor. The results of the immunofluorescence assay were consistent with these findings.

The results of the present study demonstrated that PDGF-BB was a negative factor of miR-125b expression in VSMCs. Furthermore, transfection with miR-125b mimic increased miR-125b expression in VSMCs, and promoted the cell proliferative and migratory abilities following treatment with PDGF-BB. miR-125b mimic and miR-125b inhibitor inhibited and induced AAMP and SRF expression, respectively. However, further studies are required to determine whether AAMP and SRF are target genes of miR-125b, and whether miR-125b has other target genes. Taken together, the results of the present study suggested that miR-125b is a potential therapeutic strategy for preventing the progression of ASO.

Acknowledgements

Not applicable.

Funding

Funding: The present study was supported by the Major Natural Science Project of Universities in Anhui Province (grant no. KJ2016SD38), the Key Project of Natural Science Foundation of Bengbu Medical College in Anhui Province (grant no. BYKY1862ZD) and the Scientific and technological research project of Anhui Province (grant no. 201904a07020020).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XW and YG designed the study. XW, SC, CY and ZN, YS, RL and ZG performed the experiments. SC, CY, ZN and YS performed the statistical assessments. XW, SC and YG wrote the manuscript. XW, SC and YG confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References